Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||GSK2256098 + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GSK2256098||GSK-2256098|GSK 2256098||FAK inhibitor 13||GSK2256098 is an inhibitor of focal adhesion kinase (FAK), which blocks integrin signaling and therefore, has antitumor activities (PMID: 21787277, PMID: 30992546).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 13 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PTEN mutant||uterine cancer||sensitive||GSK2256098 + Paclitaxel||Preclinical||Actionable||In a preclinical study, uterine cancer cells harboring a PTEN mutation were more sensitive to the combination of GSK2256098 and Taxol (paclitaxel) than uterine cancer cells wild-type for PTEN, resulting in decreased tumor growth in culture and in mouse models (PMID: 25833835).||25833835|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|